Effective Strategies Against Biofilm-Associated Infections

Introduction to Biofilm-Associated Infections in Otorhinolaryngology

Biofilm-associated infections (BAIs) present a formidable challenge in otorhinolaryngology (ORL), significantly contributing to the persistence and recurrence of chronic conditions such as sinusitis, otitis media, and tonsillitis. These infections arise when bacterial communities form protective biofilms on biological surfaces, leading to increased resistance against both the host immune response and conventional antibiotic therapies (1-5). The pathogenesis of these infections is complex, often involving multiple factors, including the specific anatomical features of the ORL region, the nature of the infecting pathogens, and the host’s immune response.

In the ORL context, biofilms are not merely clusters of bacteria; they represent a highly organized and dynamic community that communicates through quorum sensing (QS) mechanisms. This communication allows bacteria to coordinate their behavior, enhancing their survival and resistance to antibiotics (6-9). Biofilms can develop in niches such as the sinus cavities, middle ear, and tonsillar crypts, where they can evade immune detection and persist despite treatment efforts (10-12).

The increasing prevalence of biofilm-associated infections underscores the urgent need for innovative therapeutic strategies aimed at disrupting the biofilm structure and enhancing the efficacy of existing treatments. A comprehensive understanding of the mechanisms driving biofilm formation and the identification of effective pharmacological strategies are critical for improving patient outcomes in the management of chronic ORL infections.

Mechanisms of Biofilm Formation and Persistence

Biofilm formation in ORL infections involves a series of dynamic processes that can be categorized into three main phases: attachment, growth, and disaggregation (15).

Attachment Phase

During the attachment phase, bacteria adhere to epithelial surfaces or medical devices using surface structures, such as pili and fimbriae. This initial adhesion is crucial, as it marks the beginning of biofilm development. Pathogens like Pseudomonas aeruginosa and Staphylococcus aureus are commonly involved in forming biofilms in the sinuses and middle ear (4,5,18).

Growth Phase

As biofilms develop, bacteria proliferate and secrete extracellular polymeric substances (EPS), creating a protective matrix that stabilizes the community and allows for nutrient retention. This EPS matrix plays a significant role in the biofilm’s resistance to antibiotics and immune clearance. Quorum sensing regulates the expression of virulence factors and promotes biofilm maturation, facilitating further bacterial colonization (19-21).

Disaggregation Phase

The disaggregation phase involves the release of planktonic cells or fragments from mature biofilms, enabling colonization of new sites and contributing to recurrent infections (23-25). This process can be triggered by environmental changes, including nutrient depletion or antibiotic exposure, underscoring the resilience of biofilm-forming bacteria.

The ability of biofilms to adapt and persist highlights the need for targeted therapeutic strategies that can effectively disrupt biofilm formation and enhance treatment efficacy.

Key Pathogens Involved in Otorhinolaryngologic Infections

Numerous pathogens are implicated in biofilm formation within the ORL context, with Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae among the most prominent (Table I) (4,5,18,22,26). The presence of these pathogens in biofilms complicates treatment and increases the risk of chronic infections.

The complex interplay of these pathogens highlights the need for innovative pharmacological strategies to disrupt biofilm formation and improve treatment outcomes.

Pharmacological Approaches for Disrupting Biofilms

Addressing biofilm-associated infections requires innovative pharmacological strategies that extend beyond conventional antibiotics. Emerging approaches include:

Quorum Sensing Inhibitors (QSIs)

QSIs disrupt bacterial communication, which is essential for biofilm formation and maturation. For example, natural compounds like furanone have shown efficacy in inhibiting QS mechanisms in Pseudomonas aeruginosa, thereby preventing biofilm development (8,66).

Antibiofilm Peptides

Natural and synthetic antibiofilm peptides, such as LL-37, have demonstrated the ability to penetrate biofilm matrices and inhibit bacterial growth by disrupting cell membranes (10,11). These peptides can enhance the efficacy of conventional antibiotics, making them valuable tools in managing biofilm-associated infections.

Enzymatic Dispersal Agents

Enzymatic agents like DNase I can degrade eDNA, a critical component of the biofilm matrix, thereby disrupting the structural integrity of biofilms (74,75). This degradation can enhance antibiotic penetration and effectiveness against biofilm-forming bacteria.

Drug Repurposing

Repurposing existing drugs with known antibiofilm properties presents a cost-effective strategy for tackling biofilm-associated infections. Statins and non-steroidal anti-inflammatory drugs (NSAIDs) have shown promise in inhibiting biofilm formation and enhancing antibiotic efficacy (12-14).

Nanotechnology-Based Therapies

Nanoparticles can enhance drug delivery, improve penetration into biofilms, and possess inherent antimicrobial properties. Silver nanoparticles, for example, have demonstrated significant efficacy against biofilm-forming pathogens (101-103).

The Role of Nanotechnology and Phage Therapy in Infection Control

Nanotechnology and phage therapy represent cutting-edge approaches to managing biofilm-associated infections.

Nanotechnology

Nanoparticles can improve the solubility, stability, and bioavailability of therapeutic agents, enhancing their penetration into biofilms. For instance, silver nanoparticles have shown significant antimicrobial and antibiofilm properties against pathogens like Pseudomonas aeruginosa and Staphylococcus aureus (101,102,104,105).

Phage Therapy

Phage therapy employs bacteriophages to target and eliminate biofilm-forming bacteria. This method offers a specific approach to disrupting biofilms while preserving beneficial microbiota (109-111). Bacteriophages have been effective in treating chronic infections caused by biofilm-forming pathogens, providing a promising alternative to conventional antibiotic therapies.

Conclusion: Future Directions and Challenges in Biofilm Management

The management of biofilm-associated infections in ORL presents significant challenges, particularly due to the complex interplay of pathogenic factors and host responses. Emerging pharmacological strategies, such as QSIs, antibiofilm peptides, enzymatic dispersal agents, and drug repurposing, hold promise for improving treatment outcomes. Additionally, innovative approaches like nanotechnology and phage therapy could enhance the efficacy of existing treatments.

However, the clinical implementation of these strategies requires further research to optimize drug formulations, refine delivery methods, and explore synergistic combinations. Addressing these challenges will be crucial for developing effective therapies to manage chronic ORL infections, ultimately improving patient outcomes.

FAQ

What are biofilm-associated infections?

Biofilm-associated infections are infections caused by bacteria that form protective communities on surfaces, making them resistant to antibiotics and the immune system.

What pathogens are commonly involved in otorhinolaryngologic infections?

Common pathogens include Pseudomonas aeruginosa, Staphylococcus aureus, and Haemophilus influenzae.

What are some strategies to disrupt biofilms?

Strategies include using quorum sensing inhibitors, antibiofilm peptides, enzymatic dispersal agents, and drug repurposing.

How does nanotechnology help in managing infections?

Nanotechnology enhances drug delivery, improves penetration into biofilms, and can possess inherent antimicrobial properties.

What is phage therapy?

Phage therapy uses bacteriophages to specifically target and eliminate bacteria, including those in biofilms, offering an alternative to traditional antibiotic treatments.

References

1. Maulana, E., Kadariswantiningsih, I. N., & Nadhirah Mohd, S. (2025). Pharmacological strategies for targeting biofilms in otorhinolaryngologic infections and overcoming antimicrobial resistance (Review). BMC Infect Dis. Retrieved from https://doi.org/10.1186/s12879-025-10870-1

2. Rasool Esmaili, D., & Rahimi, E. (2025). Prevalence, virulence factors, and antibiotic resistance of Staphylococcus aureus in seafood products. BMC Infect Dis. Retrieved from https://doi.org/10.1186/s12879-025-10870-1

3. (2025). Metal-Based Approaches for the Fight against Antimicrobial Resistance: Mechanisms, Opportunities, and Challenges. BioMed Reports. Retrieved from https://doi.org/10.3892/br.2025.1973

4. (2025). Immune response against antibiotic-resistant and antibiotic-sensitive staphylococcus aureus in a rat model of implant infection. Scientific Reports. Retrieved from https://doi.org/10.1038/s41598-025-95004-y

5. (2025). In vitro wound healing effects of postbiotics derived from the gut microbiota of long-lived blind mole rats, a model of healthy ageing. Journal of Applied Microbiology. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12006833/

6. (2025). Evaluating the safety, pharmacokinetics and efficacy of phage therapy in treating fracture-related infections with multidrug-resistant Staphylococcus aureus: intravenous versus local application in sheep. Frontiers in Cellular and Infection Microbiology. Retrieved from https://doi.org/10.3389/fcimb.2025.1547250

7. (2025). Clinical and molecular characteristics of Staphylococcus aureus isolates from patients with COVID-19 in Southwest China. BMC Infect Dis. Retrieved from https://doi.org/10.1186/s12879-025-10868-9